- Jan 27, 2021- Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales- Sales growth of 28.7 percent; organic sales growth of 28.4 percent- GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent- Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020- R&D pipeline continues to be highly productive, delivering ground-breaking innovations and a steady cadence of important new products across all business areas- Issues 2021 EPS growth forecast of more than 35 percent
- Jan 26, 2021- Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic- Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers- Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision- Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology- Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads- Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends- Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide
- Jan 20, 2021- New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population
- Dec 22, 2020- 88% of Americans say it's important for COVID-19 testing to work in support of vaccine rollout- Americans agree an authorized vaccine will not change the environment overnight, indicating a need for ongoing layered protections- Despite belief in effectiveness of vaccination and testing, there is concern that other precautionary measures will decline
- Dec 17, 2020- Abbott's HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure- This life-saving technology provides new treatment option for underserved population
Dec 16, 2020- First at-home, virtually guided service to bring rapid, reliable and affordable testing into the home where the result is delivered in minutes- Abbott and eMed™ expect to deliver and administer 30 million BinaxNOW™ tests in the first quarter of 2021, with an additional 90 million in the second quarter- $25 cost for the test and service is the lowest available for at-home testing, which supports the home user to ensure a successful testing process- BinaxNOW is a highly portable, easy-to-use, 15-minute antigen test with no instrument that detects the virus when people are most infectious, which is critically important in slowing the spread of the virus- Service uses Abbott's complementary NAVICA™ app to enable the testing process and display authenticated BinaxNOW test results verified by a trained guide - and supports consumer confidence in testing at home- Dec 11, 2020- Increase reflects strength and sustainability of Abbott's diversified business- Dividend increased for 49th consecutive year- Abbott remains an S&P 500 Dividend Aristocrat
-
Dec 2, 2020- A survey, sponsored by Abbott, reveals three in four cardiologists worry the COVID-19 pandemic has restricted heart failure patients’ ability to manage their condition- In response to COVID-19, Abbott is partnering with physicians on tools and training programs to support the diagnosis and treatment of cardiovascular disease
- Nov 18, 2020- Abbott is committing $5 million over three years to the American Diabetes Association (ADA) to help close the health disparities gap for underserved diabetes communities, especially people of color and lower-income Americans
- Oct 21, 2020- Third-quarter sales growth of 9.6 percent; organic sales growth of 10.6 percent- Sales growth in Medical Devices and Diagnostics improved significantly versus prior quarter- Continues to strengthen portfolio with several recent new product approvals, including FreeStyle Libre 3, Libre Sense Glucose Sport Biosensor and MitraClip G4 heart device
- Sep 3, 2020- The LIFE-BTK trial will evaluate the company's new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK)- Esprit BTK was granted breakthrough device designation by the U.S. FDA- There are no stents or drug-coated balloons currently approved for use below the knee in the U.S.
Aug 26, 2020- Abbott's BinaxNOW™ COVID-19 Ag Card is a rapid, reliable, highly portable, and affordable tool for detecting active coronavirus infections at massive scale- Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5% in clinical study- Abbott to offer a no-charge complementary phone app, which allows people to display their BinaxNOW test results when asked by organizations where people gather, such as workplaces and schools- Company will ship tens of millions of tests in September, ramping to 50 million tests a month at the beginning of October- Jul 23, 2020- Apple‡ smartphone-compatible digital health tool fits within the company's broader NeuroSphere™ Digital Care connected care management platform, which is designed to optimize care for chronic pain and movement disorders- NeuroSphere Digital Care offers flexible virtual care options as the COVID-19 global pandemic impacts how healthcare is administered- Approval of the Patient Controller app is the latest launch under the NeuroSphere Digital Care(1) platform
- Jul 16, 2020- Worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales- Growth rates in business areas initially most impacted by COVID-19 improved significantly over the course of the second quarter- Abbott continues to strengthen its portfolio with several recent regulatory approvals, including FreeStyle Libre 2, TriClip and Gallant heart devices
- Jul 6, 2020- Next-generation Gallant™ implantable cardioverter defibrillator family of devices offers Bluetooth® capability for a more meaningful connection between patients and their doctors- Gallant ICD and CRT-D devices feature a patient-preferred design without compromising on battery longevity and compatibility with magnetic resonance imaging (MRI)
- Jun 26, 2020-- Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision-- Imaging techniques such as OCT have been shown to improve outcomes during stenting procedures¹, but remain underutilized in global clinical settings due to lack of awareness-- OCT is a high-resolution, infrared light-based imaging technique that provides unparalleled accuracy for physicians during stent implantation
- Jun 25, 2020- New data reinforce Abbott's leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies- Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott's innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings
- May 8, 2020- Researchers found the test to have 99.9% specificity and 100% sensitivity for patients tested 17 days or more after symptoms began- More than 10 million ARCHITECT antibody tests already have been shipped to hospitals and labs around the world
Apr 27, 2020-- New authorization from Health Canada allows FreeStyle Libre system to be used by frontline healthcare workers in hospitals to remotely monitor patients' glucose status to minimize exposure during COVID-19 and preserve use of personal protective equipment (PPE)-- Abbott will donate 3,000 FreeStyle Libre sensors to Canadian hospitals in need to help accelerate access to technology- Apr 16, 2020- First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent- Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19)
Apr 15, 2020- This adds to Abbott's previously announced COVID-19 molecular tests: the m2000™ lab-based test and ID NOW™ rapid point-of-care test- New antibody test will run on Abbott's ARCHITECT® i1000SR and i2000SR laboratory instruments and will expand to its new Alinity™ i system- Abbott begins shipping tomorrow and intends to distribute 4 million tests in April, ramping to 20 million in the U.S. per month in June and beyond
Apr 8, 2020-- More than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized, according to a report from the Centers for Disease Control and Prevention (CDC)¹-- FreeStyle Libre 14 day system can be used by frontline healthcare workers in hospitals to remotely monitor patients with diabetes who can scan² to minimize exposure to COVID-19 and preserve use of personal protective equipment (PPE)-- In partnership with the American Diabetes Association (ADA), Abbott will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology- Feb 20, 2020- Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world- People in Germany living with Type 1 or Type 2 diabetes on insulin showed a sustained reduction in HbA1c over one year following use of the FreeStyle Libre technology
Feb 19, 2020- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform- Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control- Jan 22, 2020- Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent- Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent- Several businesses achieved double-digit sales growth- Forecast reflects continued top-tier sales and earnings growth for 2020
-
Oct 22, 2019- One-third of Americans have heard someone say: "I drive better when I've smoked marijuana"- While drunk driving is on the decline, drug-impaired driving is on the rise[1]- Eleven states and Washington, DC, have legalized marijuana for recreational use; Illinois, Michigan are two of the next states to begin adult-use sales in 2020
- Oct 16, 2019- Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent- Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity- Continues to strengthen portfolio with a steady cadence of new product approvals, reimbursement coverage and clinical data
- Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging
- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Aug 26, 2019- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it- Abbott's diagnostic test, currently in development, is poised to be the first point-of-care blood test for assessing concussions on its next generation i-STAT™ device, providing doctors results in 15 minutes
- Aug 26, 2019- On Women's Equality Day, Abbott is publishing a blueprint for creating a high school STEM internship aimed at exposing young people, particularly girls, to STEM early and empowering other companies to download and use it- More than half of girls in a YouGov-Abbott survey say they aren't encouraged to study STEM, but 89% of girls who are urged to study STEM say they plan to pursue it in their educations
- Jul 17, 2019- Accelerated and sustainable growth driven by strong performance across portfolio- Raising full-year guidance for organic sales growth to 7 to 8 percent- Double-digit EPS growth exceeded expectations; raising full-year forecast- Long-term growth drivers - FreeStyle Libre, MitraClip and Alinity - achieving exceptional growth
- Jul 15, 2019- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair- G4 includes new clip sizes and an enhanced leaflet grasping feature
-
Jun 18, 2019- Heart failure is a manageable condition, especially if it is detected early, but people are shying away from a conversation with their doctor because they are afraid of the diagnosis- Abbott, the global leader in heart failure treatment and technologies, is using this information to increase awareness and patient-physician dialogue as heart failure diagnoses are expected to rise 46% by 2030
- Jun 13, 2019- 45% of blood donations have historically come from people over 50 years old, but that number is declining1- As more millennials bring their passion to blood donation, they can fill the gap left by aging baby boomers- Abbott, the global leader in blood screening, is asking people of all generations to sign up to give blood and help save a life on World Blood Donor Day, June 14, and throughout the year
- May 15, 2019- The YouGov-Abbott Student Loan Impact Survey shows 87% of those in college or graduating this year with student debt say finding a company with a student loan benefit is important to them- Additionally, over 6 in 10 working adults with student loans would consider switching to a company with a student loan employee benefit
- Apr 30, 2019-- Academic, military and healthcare leaders have come together to conduct a scientifically rigorous clinical trial of a blood test in development for the brain-- Research could lead to the first point-of-care blood test of its kind to help evaluate concussions within minutes
- Jan 23, 2019- Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent- Issues financial outlook for 2019, reflecting double-digit EPS growth and 6.5 to 7.5 percent organic sales growth
- Jan 16, 2019Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment